Evidence map›Paper›PMID 36483555›Full record

ArticleFrontiers in immunology2022

A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients.

Wei Cao, Weiguo Zhou, Mengying Li, Zehua Zhang, Xun Zhang, Kang Yang, Shiyi Yang, Guodong Cao, Bo Chen, Maoming Xiong

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wei CaoDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Weiguo ZhouDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Mengying LiLaboratory for Reproductive Immunology, Hospital of Obstetrics and Gynecology, Shanghai Medical School, Fudan University, Shanghai, China.
Zehua ZhangDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xun ZhangDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Kang YangDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shiyi YangDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Guodong CaoDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Bo ChenDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Maoming XiongDepartment of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
First Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: At present, there is increasing evidence that both competitive endogenous RNAs (ceRNAs) and immune status in the tumor microenvironment (TME) can affect the progression of gastric cancer (GC), and are closely related to the prognosis of patients. However, few studies have linked the two to jointly determine the prognosis of patients with GC. This study aimed to develop a combined prognostic model based on ceRNAs and immune biomarkers. Methods: First, the gene expression profiles and clinical information were downloaded from TCGA and GEO databases. Then two ceRNA networks were constructed on the basis of circRNA. Afterwards, the key genes were screened by univariate Cox regression analysis and Lasso regression analysis, and the ceRNA-related prognostic model was constructed by multivariate Cox regression analysis. Next, CIBERSORT and ESTIMATE algorithms were utilized to obtain the immune cell infiltration abundance and stromal/immune score in TME. Furthermore, the correlation between ceRNAs and immunity was found out through co-expression analysis, and another immune-related prognosis model was established. Finally, combining these two models, a comprehensive prognostic model was built and visualized with a nomogram. Results: The (circRNA, lncRNA)-miRNA-mRNA regulatory network of GC was constructed. The predictive power of ceRNA-related and immune-related prognosis models was moderate. Co-expression analysis showed that the ceRNA network was correlated with immunity. The integrated model of combined ceRNAs and immunity in the TCGA training set, the AUC values of 1, 3, and 5-year survival rates were 0.78, 0.76, and 0.78, respectively; in the independent external validation set GSE62254, they were 0.81, 0.79, and 0.78 respectively; in GSE15459, they were 0.84, 0.88 and 0.89 respectively. Besides, the prognostic score of the comprehensive model can predict chemotherapeutic drug resistance. Moreover, we found that plasma variant translocation 1 (PVT1) and infiltrating immune cells (mast cells) are worthy of further investigation as independent prognostic factors. Conclusions: Two ceRNA regulatory networks were constructed based on circRNA. At the same time, a comprehensive prognosis model was established, which has a high clinical significance for prognosis prediction and chemotherapy drug selection of GC patients.

Indexed as

RNA, Long NoncodingStomach NeoplasmsDrug ResistanceHumansPrognosisRNA, CircularTumor MicroenvironmentRNA, CircularRNA, Long NoncodingCircRNAcompeting endogenous RNA networkgastric cancerimmunocyte infiltrationmast cellplasma variant translocation 1prognostic model

Identifiers

PMID36483555
PMCPMC9723231
OpenAlexW4309688822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.